Glenbrook Capital Management filed a Form 4 regarding transactions on October 28, coinciding with a 6.93% increase in SenesTech Inc. stock.
SenesTech insiders purchased 300,770 shares worth $234k recently, signaling confidence despite losses. This net buying pattern suggests an optimistic outlook for the company.
Overview of SenesTech Inc financials and analyst estimates on TradingView, covering reported financial data and trends with standard investment disclaimers.
SenesTech Inc filed a Form 8K on October 22, 2026, resulting in a 6.53% stock price increase. The filing is considered a significant corporate event for the biotechnology firm.
SenesTech reported an 88% reduction in rat activity intensity during its Chicago Evolve pilot, correlating with a 36% drop in rodent-related 311 calls. Deployment expanded to six areas following preli
SenesTech Inc (NASDAQ:SNES) specializes in rodent fertility control using its EPA-registered product ContraPest. The page displays stock market data and company mission information.
SenesTech Inc announced preliminary Q3 2026 revenue of $1.1 million, marking its first quarter exceeding the $1 million threshold. Growth was driven by e-commerce and business-to-business sales increa
SenesTech Inc. submitted a Form 4 filing to the SEC on September 30, disclosing insider trading activity or changes in beneficial ownership of securities.
SenesTech Inc. faces a lack of verified market catalysts for its stock, with analysts advising caution against confusing its ticker with Senseonics Holdings due to different market profiles.
SenesTech Inc is projected to report an earnings loss of 36 cents per share in its upcoming financial disclosure. This earnings preview aggregates expectations from sources such as Reuters via Trading
SenesTech Inc. launched new assessment services for B2B clients to analyze rodent infestations and guide long-term management strategies. The offerings complement existing solutions like fertility con
SenesTech reported its active online subscription customer base doubled in Q2 2026, with e-commerce revenue surging 186% driven by digital marketing and sales channel management for its Evolve and Con
SenesTech Inc. announced its active online subscription base more than doubled in Q2 2026 versus Q1, fueled by e-commerce investments. This growth strengthens their recurring revenue model for rodent
SenesTech reported its active online subscriptions more than doubled in Q2 2026, driving an 186% quarter-over-quarter e-commerce growth. This supports recurring revenue for its Evolve and ContraPest r
SenesTech Inc (SNES) ranks 56th out of 65 in the Chemicals industry with a valuation score of 7.21 and a P/E ratio of -1.20. Additional financial ratios such as P/B and P/S have not yet been disclosed
SenesTech Inc. reported $2.22 million USD total revenue last year, primarily driven by its 'Evolve' segment originating from the United States.
SenesTech Inc presented a detailed financial overview for FY2025, covering stock performance, earnings data, and analyst ratings. The report includes comprehensive financial statements such as income,
Glenbrook Capital Management purchased 35,000 shares of SenesTech Inc. at $1.47/share, increasing indirect holdings to 1,057,824 shares.
SenesTech Inc filed a Form 4 on June 29, disclosing insider stock transactions. The company's stock experienced a -1.34% change during the reporting period.
SenesTech Inc (NASDAQ: SNES) financial update highlights its enterprise value to revenue forward metric, sourced from TradingView analysis.
Glenbrook Capital Management purchased 8,264 shares of SenesTech Inc. for approximately $13,563 in June 2026, increasing indirect holdings to 962,408 shares.
SenesTech Inc submitted a Form 4 filing on June 22nd, with the stock showing a 3.64% increase amidst general market activity.
SenesTech reported 20% YoY revenue growth to $2.2 million in Q4 2025, driven by e-commerce, despite a $6.4 million net loss. The company anticipates accelerated growth in 2026 with sufficient capital
Senestech Inc (SNES) reported $493K quarterly revenue and 23.90% profit growth, ranking 48th in the Chemicals industry despite low operating efficiency.
SenesTech Inc reported FY2024Q2 revenue data, noting primary income from the United States. Detailed business segment and regional contributions remain undisclosed by the company.
SenesTech Inc will attend the Lytham Partners Spring 2026 Investor Conference virtually on May 28, 2026, presenting its fertility control products for animal pest populations to investors.
SenesTech Inc. will host a virtual investor conference on May 28, 2026, featuring a webcast and one-on-one meetings. The event follows recent positive Q1 2026 results and leadership changes reported b
SenesTech Inc reported Q1 2026 earnings per share of -$0.39, missing estimates despite a narrower loss. Following the announcement, the company's stock surged by 11%.
SenesTech reported 20% revenue growth fueled by an 88% e-commerce spike and margin improvements, while announcing a CEO transition and validating its rodent control technology in the field.
SenesTech reported 2025 revenue of $2.2 million, up 20%, fueled by an 88% surge in e-commerce sales. The company also highlighted successful field validations of its Evolve rodent birth control produc
SenesTech Inc. will report its fourth-quarter and fiscal year 2025 financial results on March 12, 2026, after market close. The company will host a conference call and webcast to discuss the results.
SenesTech Inc is projected to report a loss of 30 cents per share according to Refinitiv. This earnings preview highlights investor expectations for the pest control solutions provider ahead of its up
ChemBrief